ES3058528T3 - Process for producing a tablet comprising glp-1 peptides - Google Patents

Process for producing a tablet comprising glp-1 peptides

Info

Publication number
ES3058528T3
ES3058528T3 ES20764666T ES20764666T ES3058528T3 ES 3058528 T3 ES3058528 T3 ES 3058528T3 ES 20764666 T ES20764666 T ES 20764666T ES 20764666 T ES20764666 T ES 20764666T ES 3058528 T3 ES3058528 T3 ES 3058528T3
Authority
ES
Spain
Prior art keywords
approximately
glp
peptide
tablet
feed solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20764666T
Other languages
English (en)
Spanish (es)
Inventor
Pall Ingvarsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES3058528T3 publication Critical patent/ES3058528T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20764666T 2019-09-02 2020-09-02 Process for producing a tablet comprising glp-1 peptides Active ES3058528T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19194868 2019-09-02
PCT/EP2020/074426 WO2021043803A1 (en) 2019-09-02 2020-09-02 Process for producing a tablet comprising glp-1 peptides

Publications (1)

Publication Number Publication Date
ES3058528T3 true ES3058528T3 (en) 2026-03-11

Family

ID=67840964

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20764666T Active ES3058528T3 (en) 2019-09-02 2020-09-02 Process for producing a tablet comprising glp-1 peptides

Country Status (11)

Country Link
US (1) US20220409701A1 (pl)
EP (1) EP4025192B1 (pl)
JP (1) JP7767264B2 (pl)
CN (1) CN114340655A (pl)
BR (1) BR112022002189A2 (pl)
ES (1) ES3058528T3 (pl)
HR (1) HRP20251672T1 (pl)
IL (1) IL290056B1 (pl)
PL (1) PL4025192T3 (pl)
RS (1) RS67632B1 (pl)
WO (1) WO2021043803A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
EP4370102A1 (en) * 2021-07-15 2024-05-22 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025133729A1 (en) 2023-12-18 2025-06-26 Assia Chemical Industries Ltd. Process for preparation of glp-1 peptides and dual glp-1/gip peptides having controlled particle size
CN118319871B (zh) * 2024-04-19 2025-08-05 鲁南新时代生物技术有限公司 一种司美格鲁肽药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) * 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
HRP20181447T1 (hr) * 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
ES2741507T3 (es) * 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物

Also Published As

Publication number Publication date
HRP20251672T1 (hr) 2026-02-13
IL290056A (en) 2022-03-01
WO2021043803A1 (en) 2021-03-11
BR112022002189A2 (pt) 2022-04-26
EP4025192A1 (en) 2022-07-13
IL290056B1 (en) 2026-04-01
RS67632B1 (sr) 2026-02-27
JP7767264B2 (ja) 2025-11-11
EP4025192C0 (en) 2025-12-03
JP2022545862A (ja) 2022-11-01
US20220409701A1 (en) 2022-12-29
EP4025192B1 (en) 2025-12-03
PL4025192T3 (pl) 2026-03-23
CN114340655A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
ES3058528T3 (en) Process for producing a tablet comprising glp-1 peptides
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
TWI829687B (zh) 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
KR100905428B1 (ko) 레보도파/카비도파/엔타카폰 약학적 제제
ES2370943T3 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina.
JP2022190170A (ja) グルコキナーゼ活性化剤およびｄｐｐ－ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
KR101801424B1 (ko) 날부핀-기재 제제 및 그것의 용도
RS59672B1 (sr) Čvrsti dozni oblici palbocikliba
JPH07558B2 (ja) モピダモール製剤
US12343430B2 (en) Methods of improving pharmaceutical substance solubilization and products thereof
CN115461044A (zh) 包含glp-1激动剂和组氨酸的固体组合物
TW202114730A (zh) 包括有glp-1促進劑、sglt2抑制劑及n-(8-(2-羥基苯甲醯基)胺基)辛酸鹽之固體組成物
KR101237646B1 (ko) 생체이용률이 개선된 셀레콕시브 함유 고체 분산체, 이를 포함하는 약학 조성물 및 이의 제조방법
WO2014104929A1 (ru) Фармацевтическая композиция для лечения вич-инфекции
Agiba et al. Insights into formulation technologies and novel strategies for the design of orally disintegrating dosage forms: A comprehensive industrial review
KR101778688B1 (ko) 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제
WO2020109319A1 (en) Pharmaceutical composition comprising ramipril and indapamide
WO2018154161A1 (es) Composición farmacéutica que comprende ácido 2,5 - dihidroxibencenosulfónico o una de sus sales farmacéuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricación correspondiente
CN115279348A (zh) 释放特性优异的埃索美拉唑及碳酸氢钠的药物组合物
TW202444407A (zh) 一種高生物利用度之口服glp促效劑藥物組合物
KR102485766B1 (ko) 생체이용률이 향상된 피오글리타존 함유 약학조성물
ES2742400T3 (es) Formulación farmacéutica de N-[5-[2-(3,5-dimetoxifenil)etil]-2H-pirazol-3-il]-4-[(3R,5S)-3,5-dimetilpiperazin-1-il]benzamida
KR102290295B1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
RU2267318C1 (ru) Пролонгированный антиангинальный препарат изосорбида динитрата и способ его получения
KR20200015758A (ko) 제약 조성물